Matches in SemOpenAlex for { <https://semopenalex.org/work/W2010991036> ?p ?o ?g. }
Showing items 1 to 67 of
67
with 100 items per page.
- W2010991036 endingPage "138" @default.
- W2010991036 startingPage "138" @default.
- W2010991036 abstract "1.1. The effects of ipsapirone, nefazodone, tiaspirone, BMS-20661, buspirone and gepirone on the hypothalamic-pituitary-adrenal (HPA) axis were studied. These drugs were selected because they have serontonin IA (5-HT1A) receptor-binding capability and have the potential for therapeutic activity in the treatment of major affective or anxiety disorders or both.2.2. Plasma corticosterone level was used as the end point for determining the effect of each drug on the HPA axis. Each drug increased the plasma corticosterone levels in a dose-dependent manner. The ED50 values were 0.8 mg/kg for BMS-20661, 3.5 mg/kg for gepirone, 3.9 mg/kg for buspirone, 5.3 mg/ kg for tiaspirone, 10.5 mg/kg for ipsapirone and 73.5 mg/kg for nefazodone. Ipsapirone and buspirone were more efficacious than the other four drugs.3.3. The effect of a 10-mg/kg (35 mg/kg for nefazodone) test dose of each drug reached a peak between 30 min and 1 hr, and plasma corticosterone levels generally returned to control levels after 2 hr.4.4. When the drugs were given 30 min before decapitation, in conjunction with a rotatory stress, BMS-20661 significantly inhibited the stress-induced rise, whereas ipsapirone and gepirone caused a significant increase in plasma corticosterone levels. However, when the drugs were given 2 hr before decapitation, nefazodone caused a significant decrease, whereas ipsapirone, BMS-20661 and gepirone produced significant increases in HPA axis activity. An 0800 hr dose of 0.1 mg/kg of dexamethasone suppressed the 1500 hr HPA activity by 73.1%. The 0.1-mg/kg dose of dexamethasone significantly reduced the drug-activated HPA axis activity of all of the drugs from their saline-control levels. The rank order, from least to greatest inhibitory effect, produced by this dexamethasone treatment on the drug-control levels was gepirone (−42.6%), tiaspirone (−48.9%), buspirone (−56.1%), nefazodone (−68.5%), ipsapirone (−70.0%), and BMS-20661 (−74.3%)." @default.
- W2010991036 created "2016-06-24" @default.
- W2010991036 creator A5069891095 @default.
- W2010991036 creator A5083751939 @default.
- W2010991036 creator A5091191950 @default.
- W2010991036 date "1996-06-01" @default.
- W2010991036 modified "2023-10-17" @default.
- W2010991036 title "Lipid parameters in depressed and non-depressed patients with sleep apneas syndrom" @default.
- W2010991036 doi "https://doi.org/10.1016/0924-977x(96)87943-0" @default.
- W2010991036 hasPublicationYear "1996" @default.
- W2010991036 type Work @default.
- W2010991036 sameAs 2010991036 @default.
- W2010991036 citedByCount "0" @default.
- W2010991036 crossrefType "journal-article" @default.
- W2010991036 hasAuthorship W2010991036A5069891095 @default.
- W2010991036 hasAuthorship W2010991036A5083751939 @default.
- W2010991036 hasAuthorship W2010991036A5091191950 @default.
- W2010991036 hasConcept C126322002 @default.
- W2010991036 hasConcept C134018914 @default.
- W2010991036 hasConcept C170493617 @default.
- W2010991036 hasConcept C185592680 @default.
- W2010991036 hasConcept C2775864247 @default.
- W2010991036 hasConcept C2776134451 @default.
- W2010991036 hasConcept C2777287423 @default.
- W2010991036 hasConcept C2778362415 @default.
- W2010991036 hasConcept C2778938600 @default.
- W2010991036 hasConcept C2779419675 @default.
- W2010991036 hasConcept C2780352252 @default.
- W2010991036 hasConcept C42533223 @default.
- W2010991036 hasConcept C71315377 @default.
- W2010991036 hasConcept C71924100 @default.
- W2010991036 hasConcept C98274493 @default.
- W2010991036 hasConceptScore W2010991036C126322002 @default.
- W2010991036 hasConceptScore W2010991036C134018914 @default.
- W2010991036 hasConceptScore W2010991036C170493617 @default.
- W2010991036 hasConceptScore W2010991036C185592680 @default.
- W2010991036 hasConceptScore W2010991036C2775864247 @default.
- W2010991036 hasConceptScore W2010991036C2776134451 @default.
- W2010991036 hasConceptScore W2010991036C2777287423 @default.
- W2010991036 hasConceptScore W2010991036C2778362415 @default.
- W2010991036 hasConceptScore W2010991036C2778938600 @default.
- W2010991036 hasConceptScore W2010991036C2779419675 @default.
- W2010991036 hasConceptScore W2010991036C2780352252 @default.
- W2010991036 hasConceptScore W2010991036C42533223 @default.
- W2010991036 hasConceptScore W2010991036C71315377 @default.
- W2010991036 hasConceptScore W2010991036C71924100 @default.
- W2010991036 hasConceptScore W2010991036C98274493 @default.
- W2010991036 hasLocation W20109910361 @default.
- W2010991036 hasOpenAccess W2010991036 @default.
- W2010991036 hasPrimaryLocation W20109910361 @default.
- W2010991036 hasRelatedWork W1980346197 @default.
- W2010991036 hasRelatedWork W1984563804 @default.
- W2010991036 hasRelatedWork W2034277681 @default.
- W2010991036 hasRelatedWork W2060590717 @default.
- W2010991036 hasRelatedWork W2065448957 @default.
- W2010991036 hasRelatedWork W2075772669 @default.
- W2010991036 hasRelatedWork W2088480211 @default.
- W2010991036 hasRelatedWork W2091289122 @default.
- W2010991036 hasRelatedWork W2117749122 @default.
- W2010991036 hasRelatedWork W2119923869 @default.
- W2010991036 hasVolume "6" @default.
- W2010991036 isParatext "false" @default.
- W2010991036 isRetracted "false" @default.
- W2010991036 magId "2010991036" @default.
- W2010991036 workType "article" @default.